Home  /  Resource Library  /  Can Next-Generation PI3K Inhibitors Unlock the Full Potential of the Class in Patients With B-Cell Lymphoma?

Can Next-Generation PI3K Inhibitors Unlock the Full Potential of the Class in Patients With B-Cell Lymphoma?

Article reviews Phosphoinositide 3-kinase inhibitor therapies for treatment of certain b-cell lymphomas.